Figures & data
Table 1 Key inclusion and exclusion criteria
Figure 1 Study flow chart and patient profile.
![Figure 1 Study flow chart and patient profile.](/cms/asset/7c9f49b0-7f46-4330-92db-bb168fd20938/djpr_a_164303_f0001_b.jpg)
Table 2 Subject demographics and baseline characteristics
Figure 2 Mean pain scores at the end of treatment (Days 56–60) compared with baseline.
Abbreviation: NPRS, numerical pain rating scale.
![Figure 2 Mean pain scores at the end of treatment (Days 56–60) compared with baseline.](/cms/asset/06fcd3ed-6deb-456f-98a9-062c803d3872/djpr_a_164303_f0002_b.jpg)
Figure 3 Mean pain scores over time.
Abbreviations: NPRS, numerical pain rating scale; PEMF, pulsed electromagnetic field.
![Figure 3 Mean pain scores over time.](/cms/asset/004bdb77-c575-492f-b734-4e015686869a/djpr_a_164303_f0003_b.jpg)
Figure 4 Mean pain scores over time normalized to baseline.
Abbreviation: PEMF, pulsed electromagnetic field.
![Figure 4 Mean pain scores over time normalized to baseline.](/cms/asset/0e55ae29-c31b-4239-891b-27ef589e17ab/djpr_a_164303_f0004_b.jpg)
Table 3 Primary outcome measure at 60 days
Table 4 Secondary outcome measures at 60 days
Figure 5 Time to 30% reduction in pain score is the time to response. Figures show the time to 30% reduction, which was evaluated using Kaplan–Meier statistics.
![Figure 5 Time to 30% reduction in pain score is the time to response. Figures show the time to 30% reduction, which was evaluated using Kaplan–Meier statistics.](/cms/asset/9353db52-5e0c-4216-9aaf-f78508fbdbb4/djpr_a_164303_f0005_c.jpg)
Table S1 Titles of participating sites: